Stay updated on BELINDA Clinical Trial: Tisagenlecleucel in B-cell NHL
Sign up to get notified when there's something new on the BELINDA Clinical Trial: Tisagenlecleucel in B-cell NHL page.

Latest updates to the BELINDA Clinical Trial: Tisagenlecleucel in B-cell NHL page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.6.5 has been added, replacing Revision: v3.6.4. This reflects a backend/software revision update to the page rather than a change to study details or visible content.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedPage revision label updated from v3.6.3 to v3.6.4, indicating a small update to the page metadata; no visible changes to study details are indicated by the diff.SummaryDifference0.0%

- Check49 days agoChange DetectedThe page revision was updated from v3.6.2 to v3.6.3, signaling a minor update to the page’s version. The change does not alter study details or the information presented to users.SummaryDifference0.0%

- Check56 days agoChange DetectedThe page metadata shows a new Revision tag, changing from v3.6.0 to v3.6.2. This indicates a small behind-the-scenes update to the document version without affecting visible study details.SummaryDifference0.0%

- Check70 days agoChange DetectedRecruitment status updated to 'No longer looking for participants' and the number of locations reduced from 72 to 67, with several sites removed. New user guidance sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the page revision updated to v3.6.0.SummaryDifference0.8%

- Check77 days agoChange DetectedThe page's revision label was updated to v3.5.5, replacing v3.5.4, indicating a new backend build rather than a substantive content change.SummaryDifference0.0%

Stay in the know with updates to BELINDA Clinical Trial: Tisagenlecleucel in B-cell NHL
Enter your email address, and we'll notify you when there's something new on the BELINDA Clinical Trial: Tisagenlecleucel in B-cell NHL page.